Voting Is Now Open for 2022 Oticon Focus on People Awards
SOMERSET, NEW JERSEY – Voting is now open for the 2022 Oticon Focus on People Awards at Oticon.com/FOP . Website visitors are invited to cast their votes for the 12 finalists who represent the “best of the best” from this year’s nominations in each of four categories – Student, Adult, Advocacy and Practitioner. The total…
Read More
New Study Challenges Current Knowledge About How Inner Ear Detects Low-Frequency Sound
Scientists have discovered the cochlea in the inner ear detects low-frequency sound in a manner very different than previously known, according to new research from scientists at Oregon Health & Science University and Linköping University in Sweden. The finding, published in the journal Science Advances, may make it possible to design better cochlear implants for people with…
Read More
Noah ES Surpasses 500 User Milestone
COPENHAGEN, DENMARK – HIMSA has announced that Noah ES, its new cloud-enabled Noah solution released last February in the USA and Europe, has now surpassed the 500 user milestone. Since its release seven months ago, Noah ES has steadily grown, and cloud performance has steadily improved. “When talking to our Noah ES users, one of…
Read More
FDA Approves PEDMARK® to Reduce Hearing Loss Risk in Pediatric Patients Undergoing Cisplatin Chemotherapy
RESEARCH TRIANGLE PARK, NORTH CAROLINA — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.…
Read More
Decibel Therapeutics Announces Submission of IND Application for Lead Gene Therapy Candidate DB-OTO
BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial in pediatric patients of DB-OTO,…
Read More
FCOM 2022 to Take Place in Boca Raton, November 11-13
The Florida Combined Otolaryngology Meeting (FCOM) includes the Florida Society of Otolaryngology Head and Neck Surgery (FSO-HNS), the Florida Society of Facial Plastic and Reconstructive Surgery (FSFPRS), the Network of Florida Otolaryngologists (NFO) and the Network of Medical Audiology Professionals (MedAudPro) has a speaker lineup of more than 120 presenters for its 26th annual meeting.…
Read More
Tuned Raises $2.5M Seed Round with Aim to ‘Radically Upend Status Quo’ in Hearing Care
NEW YORK CITY, NEW YORK — Tuned, a hearing health company focused on providing hearing care for all, today announced that it raised $2.5 million in seed funding, led by Idealab NY and Elements Health Ventures. Following successful pilots with companies such as RetailBound and Mishe, the injection of new capital will be used to scale employer adoption and…
Read More
Akouos Receives FDA Clearance of its IND Application for Gene Therapy Hearing Loss Treatment, AK-OTOF
BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human,…
Read More
NIH Genomics Researchers Identify Unique Set of Proteins that Restore Hearing in Zebrafish
WASHINGTON, D.C. — National Institutes of Health researchers have discovered a specific network of proteins that is necessary to restore hearing in zebrafish through cell regeneration. The study, led by investigators at the National Human Genome Research Institute (NHGRI), may inform the development of treatments for hearing loss in humans. The findings were published in Cell Genomics.…
Read More
First Patient Enrolled in Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation.…
Read More